---
title: "INNOVENT BIO granted 4.0237 million stock options and 23.1283 million restricted shares"
description: "According to the announcement from INNOVENT BIO, on March 28, 2025, the company will grant 4.0237 million stock options to 49 grantees (including directors) in accordance with the terms of the 2024 Sh"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/233673475.md"
published_at: "2025-03-28T16:56:02.000Z"
---

# INNOVENT BIO granted 4.0237 million stock options and 23.1283 million restricted shares

> According to the announcement from INNOVENT BIO, on March 28, 2025, the company will grant 4.0237 million stock options to 49 grantees (including directors) in accordance with the terms of the 2024 Share Plan, subject to acceptance by the grantees. On March 28, 2025, the company will grant 23.1283 million restricted shares to 1,261 grantees (including directors) in accordance with the terms of the 2024 Share Plan, subject to acceptance by the grantees

According to the announcement from INNOVENT BIO (01801), on March 28, 2025, the company granted 4.0237 million stock options to 49 grantees (including directors) under the terms of the 2024 Share Plan, subject to acceptance by the grantees.

On March 28, 2025, the company granted 23.1283 million restricted shares to 1,261 grantees (including directors) under the terms of the 2024 Share Plan, subject to acceptance by the grantees

### Related Stocks

- [01801.HK - INNOVENT BIO](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy | Nomura Adjusts Innovent Biologics' Price Target to HK$114.64 From HK$105.08, Keeps at Buy | [Link](https://longbridge.com/en/news/275882948.md) |
| China's Innovent clinches new Lilly deal for immunology, cancer drug development | China’s Innovent Biologics has secured a new deal with Eli Lilly for the development of immunology and oncology drugs, i | [Link](https://longbridge.com/en/news/275255059.md) |
| Innovent Biologics' Q4 Revenue Surges 60% | Innovent Biologics' Q4 Revenue Surges 60% | [Link](https://longbridge.com/en/news/274820825.md) |
| Innovent Bio's Tabosun Gets China Nod as Pre-treatment for Colon Cancer | Innovent Bio's Tabosun Gets China Nod as Pre-treatment for Colon Cancer | [Link](https://longbridge.com/en/news/270943961.md) |
| Innovent Biologics: Rising Star in Biopharma | Innovent Biologics is emerging as a leader in China's biopharma sector, shifting from generics to innovative biopharmace | [Link](https://longbridge.com/en/news/272238000.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.